Holen Sie sich die Stockscreener-App
1.85
5.71%
0.10
Handel nachbörslich:
1.74
-0.11
-5.95%
Autonomix Medical Inc Aktie (AMIX) Neueste Nachrichten
Autonomix CEO outlines follow-on expansion study expected to begin in Q2 - TipRanks
Autonomix plans expansion phase for cancer pain trial - Investing.com
AMIX Expands Clinical Trials to Target Broader Cancer Pain Marke - GuruFocus
Autonomix plans expansion phase for cancer pain trial By Investing.com - Investing.com India
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines - GlobeNewswire
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - Yahoo
Ananda Pharma, Accsys Technologies, Autonomix Medical, BitwiseSmall Cap Week in Review - Research Tree
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive financial news
Autonomix reports significant pain relief in cancer trial - Investing.com
Autonomix reports significant pain relief in cancer trial By Investing.com - Investing.com India
Autonomix Highlights Compelling Patient Testimonial Showing - GlobeNewswire
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-In-Human Proof-Of-Concept Trial in Pancreatic Cancer Pain - marketscreener.com
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic Cancer Pain Treatment | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com Australia
Autonomix advances pain treatment in cancer trials - Investing.com
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Maxim Group Initiates Coverage of Autonomix Medical (AMIX) with Buy Recommendation - Nasdaq
Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target - marketscreener.com
Autonomix Medical, Inc. to Present Innovative Neural Ablation Technology at EuroPCR 2025 - Nasdaq
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - GlobeNewswire
Revolutionary Neural Ablation Technology for Cancer Pain Management Showcased at Leading Medical Conference - Stock Titan
Autonomix Medical announces inducement grant - Medical Buyer
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autonomix Medical Expands Team with Strategic 5,000-Share Stock Option Grant to New Key Employee - Stock Titan
Autonomix Medical secures new European patent for nerve tech By Investing.com - Investing.com South Africa
Autonomix Medical Granted European Patent For Catheter-Based Neuromodulation Technology - Nasdaq
Autonomix Gains European Patent for Catheter-Based Tech - Medical Product Outsourcing
Autonomix Medical secures new European patent for nerve tech - Investing.com
Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology - marketscreener.com
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology - GlobeNewswire
Medical Breakthrough: Autonomix's New EU Patent Powers Multi-Condition Treatment Platform - Stock Titan
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline - Investing.com Australia
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline By Investing.com - Investing.com South Africa
Analyzing Globus Medical (NYSE:GMED) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix to begin U.S. clinical studies for FDA approval By Investing.com - Investing.com South Africa
Autonomix to begin U.S. clinical studies for FDA approval - Investing.com
Autonomix Medical, Inc. Engages Leading Medical Experts to - GlobeNewswire
Top Medical Experts Join Forces to Advance Revolutionary Pancreatic Cancer Pain Treatment - Stock Titan
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) - GlobeNewswire
Revolutionary Pancreatic Cancer Pain Treatment: Autonomix Medical Reveals First Clinical Results at ECIO 2025 - Stock Titan
0.74%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):